Epizyme plummets as tazemetostat studies stall
US biotech Epizyme (Nasdaq: EPZM) lost 24% of its market value on Thursday after announcing a partial clinical hold impacting its lead candidate, tazemetostat.
This orally administered, first-in-class small molecule EZH2 inhibitor is currently in Phase II development for multiple types of hematological malignancies and genetically defined solid tumors. Epizyme holds rights to the drug outside Japan and Japanese drugmaker Eisai (TYO: 4523) is the license holder in its home country and has the option to extend this to the rest of Asia.
A partial clinical hold pausing the enrollment of new patients into tazemetostat clinical trials was implemented in the second quarter of 2018 in the USA, France and Germany following a safety report of a single pediatric patient who developed a secondary T-cell lymphoblastic lymphoma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze